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Abstract
Purpose: To evaluate gold marker displacement due to needle insertion during HDR-brachytherapy for therapy of
prostate cancer.
Patients and methods: 18 patients entered into this prospective evaluation. Three gold markers were implanted
into the prostate during the first HDR-brachytherapy procedure after the irradiation was administered. Three days
after marker implantation all patients had a CT-scan for planning purpose of the percutaneous irradiation. Marker
localization was defined on the digitally-reconstructed-radiographs (DRR) for daily (VMAT technique) or weekly
(IMRT) set-up error correction. Percutaneous therapy started one week after first HDR-brachytherapy. After the
second HDR-brachytherapy, two weeks after first HDR-brachtherapy, a cone-beam CT-scan was done to evaluate
marker displacement due to needle insertion. In case of marker displacement, the actual positions of the gold
markers were adjusted on the DRR.
Results: The value of the gold marker displacement due to the second HDR-brachytherapy was analyzed in all
patients and for each gold marker by comparison of the marker positions in the prostate after soft tissue
registration of the prostate of the CT-scans prior the first and second HDR-brachytherapy. The maximum deviation
was 5 mm, 7 mm and 12 mm for the anterior-posterior, lateral and superior-inferior direction. At least one marker
in each patient showed a significant displacement and therefore new marker positions were adjusted on the DRRs
for the ongoing percutaneous therapy.
Conclusions: Needle insertion in the prostate due to HDR-brachytherapy can lead to gold marker displacements.
Therefore, it is necessary to verify the actual position of markers after the second HDR-brachytherapy. In case of
significant deviations, a new DRR with the adjusted marker positions should be generated for precise positioning
during the ongoing percutaneous irradiation.
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Modern radiation therapy procedures increasingly utilize
three-dimensional delivery techniques, which necessitate
accurate patient positioning. An improved dose delivery
by high precision technique, such as intensity modulated
therapy (IMRT or VMAT) requires an even higher
degree of accuracy in patient positioning. Therefore,
minimization of set-up errors and localization uncertain-
ties of the prostate within the patient have become criti-
cal components of highly conformal radiotherapy,
especially in IMRT and VMAT. The use of gold markers
implanted in the prostate and visualized daily using kV-
OBI imaging has therefore been employed to quantify
organ position variation and provide an accurate and
efficient method for prostate localization [1-5].
High-dose-rate (HDR)-brachytherapy is a highly pre-
cise option in prostate cancer treatment to deliver high
doses of radiation to the prostate as a boost to percuta-
neous irradiation, as monotherapy in the primary treat-
ment setting or as salvage therapy [6-16]. In the
combined treatment setting various fractionation sche-
dules and implant timing schedules of the HDR-bra-
chytherapy have been described [17-21]. If HDR-
brachytherapy is used in the combined treatment, a
further invasive approach for the implantation of the
gold marker in the prostate, which can result in possible
side effects such as bleeding and infection [22], should
be avoided. Therefore, the implantation of the gold mar-
kers in to the prostate gland should be performed at the
end of the first HDR-brachytherapy before starting the
planning for percutaneous irradiation.
When percutaneous therapy is started before comple-
tion of the HDR-brachytherapy fractions, a gold marker
displacement by the needle insertion into the prostate
gland during HDR-brachytherapy should be taken into
account and the gold marker localization should be
controlled.
The purpose of the current prospective evaluation was
to assess quantitatively gold marker displacement by
needle insertion during HDR-brachytherapy in the treat-
ment of prostate cancer. To our knowledge, this is the
first prospective analysis of the effect of needle insertion
due to HDR-brachytherapy on gold marker localization
within the prostate in the percutaneous treatment of
prostate cancer.
Methods and materials
Patients
18 sequential patients who underwent radiotherapy for
prostate cancer were enrolled in this prospective evalua-
tion. Inclusion criteria were defined as follows: prostate
carcinoma stages T2b-T3a or stages T1-T2a with Glea-
son-score ≥7a n d / o rP S A≥10 ng/ml. Patients who met
these criteria and which were intended to receive com-
bined percutaneous radiotherapy and HDR-brachyther-
apy were eligible for the study. Patient characteristics
a r es h o w ni nT a b l e1 .T h ep r i m a r yt u m o rw a ss t a g e d
clinically, according to the TNM classification of 2003
for prostate cancer [23]. Staging examination included a
physical examination of all patients. Furthermore,
abdominal ultrasound or CT-scans of the abdomen, CT-
scan of the pelvis, chest X-ray, and bone scan were
done in patients with PSA-levels ≥20 ng/ml or stage T3.
All Patients were instructed per protocol to empty the
rectum by initiation of a special diet and medication
against flatulence 2 weeks before the beginning of the
combined treatment.
Treatment
The first HDR-brachytherapy was the first treatment in
all patients. Three gold marker were implanted transper-
ineally into the prostate via a biopsy needle under ultra-
sound guidance at the end of the HDR-brachytherapy
procedure. The dimensions of the cylinder-shaped
striated soft-tissue gold markers were 1.2 mm in dia-
meter and 3 mm in height with a volume of 3.4 mm
3
(Additec, Hannover, Germany).
Table 1 Characteristics of patients entered this in study
Age 72,5 (57-77)
Tumor stage
T1c 3 (17%)
T2a 2 (11%)
T2b 3 (17%)
T2c 8 (44%)
T3a 2 (11%)
Nodal stage
N0 16 (89%)
N+ 2 (11%)
Gleason Score
≤ 6 9 (50%)
7 6 (33%)
≥ 8 3 (17%)
PSA-Level initial
< 10 10 (56%)
10-20 1 (6%)
> 20 7 (39%)
Previous treatment
no hormonal ablative therapy 9 (50%)
hormonal ablative therapy 9 (50%)
Treatment volume
prostate only 12 (67%)
whole pelvis 6 (33%)
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Brachytherapy treatment planning software (Swift
Oncentra prostate, Version 3.0, Nucletron Corporation
B.V., Veenendaal, The Netherlands). Patients received
two fractions with each 9 Gy in a two week interval.
The implantation of the HDR needles as well as the
gold marker was performed by a trained urologist using
a 7.5 MHz TRUS probe (BK medical, Herlev, Denmark).
Planning was based upon 3D ultrasound images, there-
fore axial cross sections were acquired in 1 mm steps
and transferred to the planning software (Swift Oncen-
tra Prostate, version 3.0, Nucletron Corporation B.V.,
Veendendal, The Netherlands). Contours of the prostate,
urethra and rectum were delineated in all slices by the
urologist and the radio-oncologist, whereas the PTV was
d e f i n e db yt h er a d i o - o n c o l o g i s ta st h ee n t i r ep r o s t a t e
gland without margins. The conformal treatment plan
was created during the implantation by implying a pre-
defined standard needle distribution, commonly used for
HDR-brachytherapy in our department. The plan was
generated according to the following requirements and
constrains: the prescribed dose was specified to the PTV
surface, the maximum dose to the urethra should not
exceed 125%, and 2% of the rectum volume should not
exceed 75% of the total dose.
Three days later, a CT-scan (Siemens Somatom Bal-
ance, Erlangen, Germany) was acquired using 2 mm
slices for planning of the external beam irradiation.
Patients were instructed to arrive for the planning CT-
scan with a full bladder and an empty rectum as
described before. Patient positioning on the treatment
table for the external beam radiotherapy was depending
on the indication for either a whole pelvic treatment or
a prostate gland only treatment, derived from tumor
stage, gleason-score, nodal status and PSA serum-levels.
Therefore, for external beam radiotherapy of the pros-
tate only a supine position was chosen, whereas the irra-
diation of the whole pelvis was done in a prone position
with a belly-board. No special patient selection was per-
formed for the patients analyzed in this study.
3D conformal computer-based planning was per-
formed on the Eclipse/Aria treatment planning system
(Eclipse/Aria external beam planning, Version 8.2.24,
Varian medical systems, Palo Alto, USA). The prostate
and proximal seminal vesicles were defined as the CTV.
The PTV was defined as the CTV with an additional
safety margin of 7 mm in each direction. Additionally,
in patients scheduled for pelvic lymph node irradiation,
the lymph nodes were defined and a safety margin of 10
mm in each direction was added for treatment planning.
For all Patients, a dosage of 50 Gy, with 2 Gy per frac-
tion, was prescribed. The irradiation technique included
individual optimization with conformal treatment plan-
ning and the use of a multiple field technique with
individual MLC (Multileaf Collimators) contours, or
intensity modulated (IMRT or VMAT) technique. Dose
was specified according to the ICRU 50 report [24].
After the treatment planning, one pair of orthogonal
(anterior-posterior and lateral) DRRs was generated and
the position of the gold markers could be defined. This
image set constituted the reference image pair and was
exported from the treatment planning system to the
treatment station, together with the patient treatment
plan.
One week after the first HDR-brachytherapy, percuta-
neous radiotherapy was initiated. For the verification of
the patient positioning during the percutaneous treat-
ment, verification images were taken daily (VMAT) or
weekly (IMRT, 3-D conformal multiple field-technique)
by the kilovoltage on-board imaging (kV-OBI) system
(Varian medical systems, Palo Alto, USA) as a matter of
routine in our department. Subsequently, these verifica-
tion images were compared to the digitally recon-
structed radiograph (DRR), generated during the
planning process, by a radio-oncologist with special
regard to the location of the markers was defined.
Depending on the gold marker deviation between the
verification images during treatment and the DRR, set-
up corrections for the patient positioning were
performed.
The second HDR-brachytherapy was performed as
described above. Although the gold markers were
already placed and localized prior to the insertion of the
needles, there was no block-out of the areas with gold
markers for needle insertion. After the second HDR-bra-
chytherapy, a kilovoltage cone-beam CT-scan (CBCT)
was performed. Subsequently, the CBCT-scan and the
initial CT-scan were compared by soft tissue registration
of the prostate. The positions of the markers within the
prostate were documented on each scan and the displa-
cement values were analyzed. Due to the changes of the
prostate gland in shape and volume after the second
HDR-brachytherapy we used the apex of the prostate
gland as origin for the soft tissue registration, because
the apex is, in comparison to other structures involved,
less dependent on internal influences as changing blad-
der and rectal fillings. Accordingly, the registration pro-
cess and the analysis were performed by the same radio-
oncologist to get an optimal coverage of the two
volumes. In case of marker displacement, the actual
positions of the gold markers were transferred to the
DRR for correction during the following irradiation
fractions.
Statistical analysis
Analysis was performed using the program STATIS-
TICA 7.0 (Stat Soft, Palo Alto, USA). For evaluation of
the statistical significance (values < 0.05) of differences,
Herrmann et al. Radiation Oncology 2012, 7:24
http://www.ro-journal.com/content/7/1/24
Page 3 of 7either the Wilcoxon-matched-pairs test or the Mann-
Withney-U test was performed. For the quantification of
the gold marker displacements, statistical data such as
the mean, standard deviation (SD) and minimum and
maximum displacement values were calculated. The
gold marker displacement after the second HDR-bra-
chytherapy (CBCT) as well as the daily or weekly gold
marker deviations during irradiation (kV-OBI) have
been analyzed and compared. For each patient, the
mean gold marker deviation was calculated by analysis
of the average deviations measured on each kV-OBI
image performed during the external beam radiotherapy.
We did not distinguish between random and systematic
errors. The associated standard deviation was also calcu-
lated. Furthermore, the mean displacement of the entire
group was computed by averaging over all patients.
Results
18 patients were included into this prospective
evaluation.
Gold marker displacement analysis during external beam
radiotherapy
A total of 214 kV-OBI images were acquired over the
course of the study. For all patients, the maxima,
minima, means and standard deviations of the magni-
tude of gold marker displacement were as follows: for
anterior-posterior (AP) 19 mm, 0.0 mm, -1.6 ± 5 mm,
for lateral (LR) 14 mm, 0.0 mm, 0.6 ± 4 mm, for super-
ior-inferior (SI) directions 11 mm, 0.0 mm, 0.8 ± 5 mm.
The maxima, minima, means and standard deviations
of the magnitude of gold marker displacement in
patients receiving percutaneous radiotherapy for the
prostate only (n = 154 kV-OBI images), were as follows:
for anterior-posterior (AP) -13 mm, 0.0 mm, -2 ± 4
mm, for lateral (LR) 12 mm, 0.0 mm, 1 ± 4 mm, and
for superior-inferior (SI) directions 8 mm, 0.0 mm, 1 ±
4 mm (Table 1).
The maxima, minima, means and standard deviations
of the magnitude of gold marker displacement in
patients receiving external beam radiotherapy of the pel-
vic nodes (n = 60 kV-OBI images) were as follows: for
anterior-posterior (AP) 19 mm, 0.0 mm, -0.6 ± 5 mm,
for lateral (LR) -14 mm, 0.0 mm, -0.6 ± 4 mm, and
superior-inferior (SI) directions -8 mm, 0.0 mm, -1 ± 4
mm (Table 1).
Gold marker displacement analysis after HDR-
brachytherapy
A total of 54 gold markers were implanted. In every
patient, a CBCT-scan was acquired after the second
HDR-brachytherapy, prior to the following external
beam irradiation fraction. During the first week of exter-
nal beam radiotherapy, prior the second HDR-
brachytherapy, the marker position showed no signifi-
cant deviation or migration on the verification images in
comparison to the DRRs of the planning CT-scans.
Following the second HDR-brachytherapy, the displa-
cement of each gold marker within the prostate was ana-
lyzed after registration of the CBCT to the planning CT-
scan. The maxima, minima, means and standard devia-
tions of the magnitude of gold marker displacement were
as follows: for anterior-posterior (AP) 5 mm, 0.0 mm,
-0.4 ± 2 mm, for lateral (LR) -7 mm, 0.0 mm, 0.4 ± 2
mm, and for superior-inferior (SI) directions 12 mm, 0.0
mm, -3 ± 4 mm (Table 2). Our analysis of the magnitude
of gold marker displacement between the two bra-
chytherapy procedures showed significant differences in
the superior-inferior (SI) direction compared as well to
the anterior-posterior (AP) direction (p = 0.0007) as to
the lateral (LR) direction (p = 0.00003). No statistical sig-
nificant difference was found in the anterior-posterior
direction compared to the lateral direction (p = 0.08).
Comparison of the gold marker localization changes after
the second HDR-brachytherapy and during the following
percutaneous irradiation
The magnitude of gold marker deviation in the SI direc-
tion was much more pronounced in the analysis after
the second HDR-brachytherapy than during the follow-
ing external beam radiotherapy period for both pelvic
node and prostate only irradiation. However, this differ-
ence was not statistical significant. Analysis of the gold
marker deviation values in the AP and LR direction
showed contrary results. The deviation values for both
directions were statistical significant lower in the analy-
sis after the second HDR-brachytherapy compared to
the deviation values in the analysis during the following
external beam radiotherapy, for both pelvic node (p =
0.007) and (p = 0.02) and prostate only irradiation (p =
0.0002) and (p = 0.00004), respectively.
Discussion
Modern percutaneous radiation therapy procedures
increasingly utilize three-dimensional (3D) conformal or
intensity-modulated (IMRT or VMAT) techniques,
which necessitate a maximum degree of accuracy in
patient positioning and tumour targeting. The use of
radio-opaque gold markers implanted in the prostate
gland and visualized daily by using kV-OBI imaging has
therefore been employed. These markers provide the
quantification of organ position variations and therefore
allow for a reliable coverage of the target by increased
accuracy in prostate localization [1-5]. However, when
gold markers are used, at least two aspects have to be
considered, on the one hand gold marker migration
itself within the prostate gland and on the other hand
gold marker migration by deviation of the whole
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nal influences, e.g. filling of the bladder or the rectum.
Therefore, gold marker migration has been studied by
several investigators to quantify and characterize the
movements of the markers within the prostate gland. It
has been established that there is a migration of the
markers within the prostate gland, but this deviations
were not shown to be significant [25,26]. Furthermore,
gold marker displacement due to prostate movement
during external beam radiotherapy has been analyzed in
many studies as well [1-5].
The regular magnitude of displacement of the gold mar-
ker during external beam radiotherapy showed compar-
able values in the superior-inferior direction and
significant higher values in the anterior-posterior and the
lateral direction. The analysis of the marker displacement
values during percutaneous radiotherapy shows the corre-
sponding displacements values as described before, caused
by inter- and intrafraction motion of the whole prostate
gland itself due to multifaceted external and internal influ-
encing factors [1-5]. The aspect of a possible marker dis-
placement or movement due to needle insertion during a
HDR-brachytherapy is a further important source of inter-
ference in the use of gold markers for prostate localization.
The impact of the needle insertion on the position of gold
markers within the prostate gland and its relevance for the
accuracy of patient positioning during the following
percutaneous treatment has not been considered or ana-
lyzed until now.
For the evaluation of the gold marker deviations the
CT-scan after the first HDR-brachytherapy and the
CBCT-scan after the second HDR-brachytherapy were
registered and analyzed by the same radio-oncologist
during a replanning procedure. Soft tissue matching of
the prostate gland was performed on every patient for
the analysis of the marker deviations. Due to the changes
of the prostate gland in shape and volume after the sec-
ond HDR-brachytherapy in all but 2 cases (Table 3), the
registration process was done according to predefined
specifications in our department. We defined the apex of
t h ep r o s t a t eg l a n da st h eo r i g i nf o rt h es o f tt i s s u er e g i s -
tration of the prostate, to achieve reliable, accurate and
comparable results. Among all involved structures in the
region of the small bowel, the apex appears to be less
dependent on internal influences as different bladder and
rectal fillings. In view of the general difficulties in pros-
tate localization in CT-scans during a normal planning
process, our predefined specifications for the soft tissue
matching of the prostate gland proved to be reliable,
comparable and safe in daily practice.
Our data showed gold marker deviations in all directions
for each patient, as well in the analysis of the marker loca-
lizations after the second HDR-brachytherapy as in the
analysis during the following external beam radiotherapy.
Table 2 Error of gold marker displacement after HDR-brachytherapy and during irradiation for each patient
Patient gold marker displacement after second HDR-brachytherapy gold marker displacement during external beam radiotherapy
Superior-inferior
maximum,
minimum, mean, SD
(mm)
Anterior-posterior
maximum,
minimum, mean, SD
(mm)
Left-right
maximum,
minimum, mean SD
(mm)
Superior-inferior
maximum,
minimum, mean, SD
(mm)
Anterior-posterior
maximum,
minimum, mean
SD (mm)
Left-right
maximum,
minimum, mean SD
(mm)
1 2, 0.0, 0.7 ± 1 0.0, 0.0,0.0 ± 0.0 2, 0.0, 2 ± 1 4, 0.0, 0.2 ± 3 -5, 0.0, 0.8 ± 4 -4, 2, -2 ± 3
2 0.0, 0.0, 0.0 ± 0.0 -2, 0.0, -0.7 ± 1 -2, 0.0, -0.7 ± 1 8, 0.0, 1 ± 7 -4, 0.0, -2 ± 2 -4, -1, -3 ± 2
3 2, 0.0, 0.7 ± 1 5, 4, 5 ± 0.6 -3, -1, -2 ± 1 -5, 0.0, -0.6 ± 2 -13, 0.0, -4 ± 3 8, -3, 2 ± 0.3
4 2, 0.0, 0.7 ± 1 -2, 0.0, -7 ± 1 0.0, 0.0, 0.0 ± 0.0 -6, -2, -4 ± 2 -6, 0.0, -3 ± 2 -7, 0.0, -3 ± 3
5 12, 6, 9 ± 3 -1, 0.0, -0.3 ± 0.6 3, -2, 1 ± 3 11, 0.0, 4 ± 5 -6, 0.0, -2 ± 3 -8, 0.0, -4 ± 4
6 2, 0.0, 1 ± 1 0.0, 0.0, 0.0 ± 0.0 -1, 0.0, -0.3 ± 0.6 3, 0.0, 1 ± 2 -7, 0.0, -4 ± 2 3, 0.0, 0.1 ± 1
7 6, 6, 6 ± 0.0 0.0, 0.0, 0.0 ± 0.0 -1, 0.0, -0.3 ± 0.6 -6, 0.0, -2 ± 3 6, 0.0, 0.0 ± 4 4, 0.0, 1 ± 2
8 12, 2, 8 ± 5 4, 3, 4 ± 0.6 -3, 0.0, -2 ± 2 11, -2, 5 ± 7 -6, 0.0, -2 ± 3 -8, 0.0, -3 ± 4
9 6, -2, 1 ± 4 -3, 0.0, -1 ± 2 2, 0.0, 0.7 ± 1 11, -1, -6 ± 4 12, 0.0, -15 ± 4 -10, 0.0, 2 ± 4
10 8, 2, 6 ± 3 -2, 0.0, -0.7 ± 1 -7, 0.0, -2 ± 4 -11, -5, -7 ± 3 -8, 0.0, -5 ± 4 -9, 0.0, -6 ± 4
11 2, 0.0, 0.7 ± 1 0.0, 0.0, 0.0 ± 0.0 0.0, 0.0, 0.0 ± 0.0 7, 0.0, 0.4 ± 4 -8, 0.0, -0.6 ± 4 -8, -2, -3 ± 3
12 2, 0.0, 0.7 ± 1 -3, 0.0, -1 ± 2 -4. 0.0, -2 ± 2 -5, 0.0, 0.8 ± 3 -5, 2, 0.2 ± 10 -3, 0.0, 0.0 ± 2
13 -2, -2, -2 ± 0.0 4, 0.0, 1 ± 2 -3, 0.0, 1 ± 2 -8, 0.0, -5 ± 3 -5, 0.0, -1 ± 2 -9, 0.0, -0.6 ± 4
14 8, 6, 7 ± 1 5, 4, 4 ± 0.6 -3, 1, -1 ± 2 -9, 1, 1 ± 4 19, -1, 3 ± 8 -14, -2, 0.7 ± 7
15 0.0, 0.0, 0.0 ± 0.0 -3, 0.0 -1 ± 2 4, 0.0, 2 ± 2 8, 0.0, 2 ± 3 -13, -1, -3 ± 5 12, 0.0, 3 ± 3
16 8, -4, 0.0 ± 7 -4, 2, -1 ± 3 -2, -1, -1 ± 0.6 -8, 0.0, -4 ± 4 -6, 1, -3 ± 3 9, 1, 4 ± 3
17 4, 3, 4 ± 0.6 0.0, 0.0, 0.0 ± 0.0 -1, 0.0, -0.3 ± 0.6 5, 1, 2 ± 2 10, 2, 34 3, -1, 0.3 ± 2
18 5, 0.0, 2 ± 3 0.0, 0.0, 0.0 ± 0.0 0.0, 0.0, 0.0 ± 0.0 11, 1, 5 ± 3 -13, 0.0, -0.6 ± 5 8, 1, 5 ± 2
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second HDR-brachytherapy in each patient before conti-
nuing external beam irradiation showed statistically signif-
icant deviation values in the superior-inferior direction
compared to both the anterior-posterior and lateral direc-
tion. Therefore, needle insertion through the perineum
into the prostate gland consequentially results in a devia-
tion of the markers which follows the direction of the nee-
dles inserted during HDR-brachytherapy.
Possible reasons for the displacement of the gold mar-
kers caused by insertion of needles during HDR-bra-
chytherapy are localized bleedings into the tissue of the
prostate gland, or a dislocation of prostate tissue inside
the gland due to needle insertion. Furthermore, a direct
contact between the gold marker and the inserted nee-
dle should be considered as possible explanation.
Our data show, that gold marker displacement eithin
the prostate gland can be caused by HDR-brachyther-
apy. This displacement could possibly result in an insuf-
ficient percutaneous treatment with incomplete covering
of the target because of an incorrect marker based
image guidance, especially the prostate within small
safety margin (7 mm), when actual marker positions
were not considered.
In some patients the displacement was more pro-
nounced than in other patients (Table 3). This could be
due to different prostate volumes and needle insertions.
T h ep r o s t a t ev o l u m ed u r i n gt h ef i r s ta n ds e c o n dH D R -
brachytherapy was in minimum 18 and 21 cm
3,i nm a x i -
mum 66 and 89 cm
3 and in mean 32 and 42 cm
3 respec-
tively. The quantity of needles used for the HDR-
brachytherapy was in minimum 14 and 15, in maximum
18 and 17 and in mean 16 and 17, respectively. We both
observed an increase (14 patients), a decrease (2 patients)
and no change (2 patients) in prostate volumes after
HDR-brachytherapy including application of the gold mar-
kers, as it has previously been published by our depart-
ment [27]. In the analyzed 18 patients no correlation was
seen between the volume change of prostate and magni-
tude of seed gold marker displacement. Though we did
not find a difference in the displacement values between
small and large prostate volumes this could be more
pointed out in a larger patient population.
Our study included only a small number of patients,
but a significant gold marker displacement was observed
in the superior-inferior direction compared to the ante-
rior-posterior and lateral directions after the second
HDR-brachtherapy in some patients. In conclusion, the
control and subsequent adjustment of the actual marker
localization on the DRR after HDR-brachytherapy is
necessary for precise correction during the following
percutaneuos treatment, whereas it is also possible to
initiate a complete new planning process using new
planning CT-scans. Another option is the implementa-
tion of a different treatment schedule. The completion
of HDR-brachytherapy implants prior to the planning of
Table 3 Volume changes of the prostate gland for each patient between CT-scan after first HDR and CBCT-scan after
second HDR-brachytherapy
Patient First HDR-brachytherapy Second HDR-brachytherapy
Number of needles used Volume of the prostate gland (ml) Number of needles used Volume of the prostate gland (ml)
1 17 45 18 52
2 17 45 18 45
3 14 20 17 27
4 14 18 15 21
5 15 24 16 39
6 15 31 18 37
7 16 37 18 56
8 16 22 17 27
9 18 66 18 89
10 16 33 17 38
11 18 51 17 42
12 18 22 17 24
13 18 40 17 54
14 16 34 17 26
15 17 57 18 69
16 18 23 17 38
17 16 22 18 28
18 14 28 17 45
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marker displacements due to manipulations of the pros-
tate gland during external beam irradiation, as we do
now as standard approach in our department.
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